These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37473516)

  • 21. Metastatic disease from uveal melanoma: treatment options and future prospects.
    Carvajal RD; Schwartz GK; Tezel T; Marr B; Francis JH; Nathan PD
    Br J Ophthalmol; 2017 Jan; 101(1):38-44. PubMed ID: 27574175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver metastasis in uveal melanoma - treatment options and clinical outcome.
    Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A
    Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
    BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model.
    Anbari S; Wang H; Arulraj T; Nickaeen M; Pilvankar M; Wang J; Hansel S; Popel AS
    NPJ Syst Biol Appl; 2024 Sep; 10(1):108. PubMed ID: 39349498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of new therapeutic options for the treatment of uveal melanoma.
    Wang JZ; Lin V; Toumi E; Wang K; Zhu H; Conway RM; Madigan MC; Murray M; Cherepanoff S; Zhou F; Shu W
    FEBS J; 2021 Nov; 288(21):6226-6249. PubMed ID: 33838075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
    Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
    Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uveal melanoma.
    Spagnolo F; Caltabiano G; Queirolo P
    Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tebentafusp: First Approval.
    Dhillon S
    Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent approaches for the treatment of uveal melanoma: Opportunities and challenges.
    Khan SA; Almalki WH; Arora S; Kesharwani P
    Crit Rev Oncol Hematol; 2024 Jan; 193():104218. PubMed ID: 38040071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New immunotherapy approaches as the most effective treatment for uveal melanoma.
    Eteghadi A; Ebrahimi M; Keshel SH
    Crit Rev Oncol Hematol; 2024 Feb; 194():104260. PubMed ID: 38199429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
    Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
    Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uveal melanoma: Current evidence on prognosis, treatment and potential developments.
    Gelmi MC; Jager MJ
    Asia Pac J Ophthalmol (Phila); 2024; 13(2):100060. PubMed ID: 38641203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic uveal melanoma: biology and emerging treatments.
    Woodman SE
    Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
    Sacco JJ; Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Holland C; Sato T
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
    Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
    Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.
    Reschke R; Enk AH; Hassel JC
    Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy.
    Lv X; Ding M; Liu Y
    Front Immunol; 2022; 13():848455. PubMed ID: 35309331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.
    Johnson DB; Bao R; Ancell KK; Daniels AB; Wallace D; Sosman JA; Luke JJ
    J Natl Compr Canc Netw; 2019 Feb; 17(2):114-117. PubMed ID: 30787124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.